MenopauseNCT06800560
The Development, Validation and Application of a Novel Questionnaire Developed by ZOE Ltd Measuring Menopause Symptoms and Subjective Quality of Life
An observational study of Menopause, run by Zoe Global Limited at 1 site in United Kingdom.
Trial summary
The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Read more about this study
- Who is it for?
- Ages 37 to 70 years, women only
- Conditions the study is for
- Menopause
- What is being tested?
- MenoScale, Greene Climacteric Scale and RAND 36-Item Health Survey 1.0
- How many people
- 1,100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 12 Nov 2024to 17 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 37 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The participants for this study will be recruited from the ZOE Health Study, which is a community science app in which participants are actively involved in logging lifestyle and health data, and those who have consented to receiving the ZOE newsletter.
Who may be able to join
- Female (sex assigned at birth) Aged 37 - 70 years Peri- or postmenopausal (self-reported)
Who cannot join
- Currently pregnant and/or lactating History of hysterectomy or oophorectomy History of treatment-induced menopause Body mass index of < 18.5 Subject is taking > 5 prescribed medications Subject is unable to provide informed consent online Subject is unable understand the participant information sheet Subject is unable to complete the questionnaires online
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Validating a Novel Instrument Developed by ZOE Ltd. to Measure Menopause-related Symptoms and Quality of Life
The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Firstly, the symptoms assessed are informed by prevalence, as identified from a large cohort. Secondly, the language used to ask about symptoms is modern and accessible as determined through qualitative user research. Thirdly, the impact on quality of life is assessed. Finally, it is already being offered online and completely open access.
The overall aim of this study is to validate the reliability and validity of the MenoScale as an instrument to measure menopausal symptoms and the related subjective impact on quality of life (QoL).
Read the detailed description
Menopause, a crucial phase in a woman's life, is the disappearance of menstruation for 12 months or longer due to depleted ovarian activity. On average, this stage accounts for over one-third of a woman's lifespan (1). In the United Kingdom (UK), the average age of menopause is 51 years, with the transitional period known as perimenopause occurring from around 45 years (2). As of 2017, there are 13 million menopausal women in the UK, with one third being aged 50 years and over in full time employment (3). It is crucial to have reliable and accessible methods for measuring and tracking symptoms in order to establish medical and lifestyle interventions which may aid in alleviating the burden of these symptoms.
All stages of menopause is accompanied by a wide variety of fluctuating symptoms and subjective experiences of women. Therefore, an online, validated questionnaire offers women the opportunity to monitor their symptoms in real- time which ultimately will: 1) raise awareness by increasing understanding around menopause; 2) empower women to track and manage their menopause themselves; and 3) facilitate conversations by providing data-backed insights to enhance discussions with healthcare providers.
The study has four main objectives:
- Validate the ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
- Validate the ability of the MenoScale to measure the impact that symptoms have on overall QoL in comparison to a widely-used QoL scale.
- Evaluate the test-retest reliability of the MenoScale.
- Explore relationships between menopause-related symptoms and dietary intake.
RECRUITMENT: Potential participants will be recruited from those who are enrolled onto the ZOE Health Study as well as their friends and family. Potential participants will be contacted via email and provided with a Participant Information Sheet. Participants will be given a minimum of 24 hours after receiving the information sheet to decide whether they would like to take part in the study. Those that would like to take part in the study will be screened using an online form via a secure survey platform and eligible participants will then be asked to provide informed consent.
STUDY DESIGN: Once informed consent has been provided all participants will be asked to complete online versions of a demographics questionnaire (ethnicity, education level, menopause history [age symptoms started, age of last period], HRT usage [type and time period taken]), the MenoScale, Green Climacteric Scale, and the Short Form-36. Participants will also be asked to completed a food frequency questionnaire at baseline only. Participants will be contacted seven days later to repeat the same procedures - except for the demographics, health questionnaire and FFQ. Completion of all questionnaires is expected to take approximately 1 hour at baseline and 15 minutes at follow up.
Biological samples will not be collected in this study, nor will previously collected data be analysed.
The only primary data collection to occur during this study is the following:
- Menopause symptoms questionnaires: MenoScale and Green Climacteric Scale
- Quality of life questionnaire: Short Form 36
- Dietary questionnaire: Predict-Food Frequency Questionnaire-v1
- Demographics questionnaire: ethnicity, BMI, HRT usage, education
References:
- Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303.
- Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855.
- Menopause transition: effects on women's economic participation - GOV.UK [https://www.gov.uk/government/publications/menopause-transition-effects-on-womens-economic-participation]
- Conditions
- Menopause
- Being tested
- MenoScale, Greene Climacteric Scale, RAND 36-Item Health Survey 1.0, PREDICT-FFQ-v1
- Keywords
- Menopause, Questionnaire Validation, Perimenopause, Postmenopause, Quality of Life, Diet Quality, Menopausal Symptoms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MenoScaleOther
Menopause symptom questionnaire
Greene Climacteric ScaleOther
Menopause symptom questionnaire
RAND 36-Item Health Survey 1.0Other
Also called Short Form 36, SF36, SF-36
Quality of life questionnaire
PREDICT-FFQ-v1Other
Also called Food frequency questionnaire, FFQ
Food frequency questionnaire
| Study group | Role | What they receive |
|---|---|---|
| PeriHRT - perimenopausal women currently using hormone replacement therapy | Sub-cohort Receives: Other: MenoScale; Other: Greene Climacteric Scale; Other: RAND 36-Item Health Survey 1.0; Other: PREDICT-FFQ-v1 | |
| Peri - perimenopausal women not using hormone replacement therapy | Sub-cohort Receives: Other: MenoScale; Other: Greene Climacteric Scale; Other: RAND 36-Item Health Survey 1.0; Other: PREDICT-FFQ-v1 | |
| PostHRT - postmenopausal women currently using hormone replacement therapy | Sub-cohort Receives: Other: MenoScale; Other: Greene Climacteric Scale; Other: RAND 36-Item Health Survey 1.0; Other: PREDICT-FFQ-v1 | |
| Post - postmenopausal women not using hormone replacement therapy | Sub-cohort Receives: Other: MenoScale; Other: Greene Climacteric Scale; Other: RAND 36-Item Health Survey 1.0; Other: PREDICT-FFQ-v1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
MenoScale validity for menopause symptoms
The ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
Measured: Baseline
Secondary outcomes (3)
MenoScale validity for quality of life
- The ability of the MenoScale to measure the impact that symptoms have on overall quality of life in comparison to a widely-used quality of life scale.
Measured: Baseline
MenoScale reliability
The reliability of the MenoScale to be repeated and how this compares to the Green Climacteric Scale
Measured: Baseline and 1 week later
Diet quality
Associations between healthy dietary patterns, food groups and menopausal symptoms
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2025
- Study start12 Nov 2024
- Primary completion11 Dec 2024
- Study completion17 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for MenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zoe Global Limited
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sarah Berry, PhD, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06800560
- Sponsor's protocol ID
- MenoScale Validation
- Status last verified
- Jan 2025
- First submitted
- 12 Nov 2024
- Last updated
- 30 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855. Epub 2023 Dec 21.
PubMed 38171939Bermingham KM, Linenberg I, Hall WL, Kade K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303. Epub 2022 Oct 18.
PubMed 36270905
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validating a Novel Instrument Developed by ZOE Ltd. to Measure Menopause-related Symptoms and Quality of Life
- ClinicalTrials.gov ID
- NCT06800560
- Acronym / sponsor ID
- MenoScale Validation
- Conditions
- Menopause
- Keywords
- Menopause, Questionnaire Validation, Perimenopause, Postmenopause, Quality of Life, Diet Quality, Menopausal Symptoms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,100 participants (actual)
- Lead sponsor
- Zoe Global LimitedUniversity, hospital or other
- Study start
- 12 Nov 2024 (actual)
- Primary completion
- 11 Dec 2024 (actual)
- Study completion
- 17 Dec 2024 (actual)
- First posted
- 30 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The MenoScale has been developed from the most common symptoms identified in over 70,000 women to reflect symptom prevalence and user-friendly terminology. It builds and improves on pre-existing scoring tools in four main ways. Firstly, the symptoms assessed are informed by prevalence, as identified from a large cohort. Secondly, the language used to ask about symptoms is modern and accessible as determined through qualitative user research. Thirdly, the impact on quality of life is assessed. Finally, it is already being offered online and completely open access.
The overall aim of this study is to validate the reliability and validity of the MenoScale as an instrument to measure menopausal symptoms and the related subjective impact on quality of life (QoL).
Detailed description
Menopause, a crucial phase in a woman's life, is the disappearance of menstruation for 12 months or longer due to depleted ovarian activity. On average, this stage accounts for over one-third of a woman's lifespan (1). In the United Kingdom (UK), the average age of menopause is 51 years, with the transitional period known as perimenopause occurring from around 45 years (2). As of 2017, there are 13 million menopausal women in the UK, with one third being aged 50 years and over in full time employment (3). It is crucial to have reliable and accessible methods for measuring and tracking symptoms in order to establish medical and lifestyle interventions which may aid in alleviating the burden of these symptoms.
All stages of menopause is accompanied by a wide variety of fluctuating symptoms and subjective experiences of women. Therefore, an online, validated questionnaire offers women the opportunity to monitor their symptoms in real- time which ultimately will: 1) raise awareness by increasing understanding around menopause; 2) empower women to track and manage their menopause themselves; and 3) facilitate conversations by providing data-backed insights to enhance discussions with healthcare providers.
The study has four main objectives:
- Validate the ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
- Validate the ability of the MenoScale to measure the impact that symptoms have on overall QoL in comparison to a widely-used QoL scale.
- Evaluate the test-retest reliability of the MenoScale.
- Explore relationships between menopause-related symptoms and dietary intake.
RECRUITMENT: Potential participants will be recruited from those who are enrolled onto the ZOE Health Study as well as their friends and family. Potential participants will be contacted via email and provided with a Participant Information Sheet. Participants will be given a minimum of 24 hours after receiving the information sheet to decide whether they would like to take part in the study. Those that would like to take part in the study will be screened using an online form via a secure survey platform and eligible participants will then be asked to provide informed consent.
STUDY DESIGN: Once informed consent has been provided all participants will be asked to complete online versions of a demographics questionnaire (ethnicity, education level, menopause history [age symptoms started, age of last period], HRT usage [type and time period taken]), the MenoScale, Green Climacteric Scale, and the Short Form-36. Participants will also be asked to completed a food frequency questionnaire at baseline only. Participants will be contacted seven days later to repeat the same procedures - except for the demographics, health questionnaire and FFQ. Completion of all questionnaires is expected to take approximately 1 hour at baseline and 15 minutes at follow up.
Biological samples will not be collected in this study, nor will previously collected data be analysed.
The only primary data collection to occur during this study is the following:
- Menopause symptoms questionnaires: MenoScale and Green Climacteric Scale
- Quality of life questionnaire: Short Form 36
- Dietary questionnaire: Predict-Food Frequency Questionnaire-v1
- Demographics questionnaire: ethnicity, BMI, HRT usage, education
References:
- Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303.
- Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855.
- Menopause transition: effects on women's economic participation - GOV.UK [https://www.gov.uk/government/publications/menopause-transition-effects-on-womens-economic-participation]
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PeriHRT - perimenopausal women currently using hormone replacement therapy | – | Other: MenoScale, Other: Greene Climacteric Scale, Other: RAND 36-Item Health Survey 1.0, Other: PREDICT-FFQ-v1Sub-cohort |
| Peri - perimenopausal women not using hormone replacement therapy | – | Other: MenoScale, Other: Greene Climacteric Scale, Other: RAND 36-Item Health Survey 1.0, Other: PREDICT-FFQ-v1Sub-cohort |
| PostHRT - postmenopausal women currently using hormone replacement therapy | – | Other: MenoScale, Other: Greene Climacteric Scale, Other: RAND 36-Item Health Survey 1.0, Other: PREDICT-FFQ-v1Sub-cohort |
| Post - postmenopausal women not using hormone replacement therapy | – | Other: MenoScale, Other: Greene Climacteric Scale, Other: RAND 36-Item Health Survey 1.0, Other: PREDICT-FFQ-v1Sub-cohort |
Who may qualify
- Ages
- 37 to 70 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The participants for this study will be recruited from the ZOE Health Study, which is a community science app in which participants are actively involved in logging lifestyle and health data, and those who have consented to receiving the ZOE newsletter.
Key inclusion criteria (1 listed)
- Female (sex assigned at birth) Aged 37 - 70 years Peri- or postmenopausal (self-reported)
Key exclusion criteria (1 listed)
- Currently pregnant and/or lactating History of hysterectomy or oophorectomy History of treatment-induced menopause Body mass index of < 18.5 Subject is taking > 5 prescribed medications Subject is unable to provide informed consent online Subject is unable understand the participant information sheet Subject is unable to complete the questionnaires online
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MenoScaleMenopause symptom questionnaire | Other | Peri - perimenopausal women not using hormone replacement therapy, PeriHRT - perimenopausal women currently using hormone replacement therapy, Post - postmenopausal women not using hormone replacement therapy, PostHRT - postmenopausal women currently using hormone replacement therapy |
| Greene Climacteric ScaleMenopause symptom questionnaire | Other | Peri - perimenopausal women not using hormone replacement therapy, PeriHRT - perimenopausal women currently using hormone replacement therapy, Post - postmenopausal women not using hormone replacement therapy, PostHRT - postmenopausal women currently using hormone replacement therapy |
| RAND 36-Item Health Survey 1.0Also: Short Form 36, SF36, SF-36Quality of life questionnaire | Other | Peri - perimenopausal women not using hormone replacement therapy, PeriHRT - perimenopausal women currently using hormone replacement therapy, Post - postmenopausal women not using hormone replacement therapy, PostHRT - postmenopausal women currently using hormone replacement therapy |
| PREDICT-FFQ-v1Also: Food frequency questionnaire, FFQFood frequency questionnaire | Other | Peri - perimenopausal women not using hormone replacement therapy, PeriHRT - perimenopausal women currently using hormone replacement therapy, Post - postmenopausal women not using hormone replacement therapy, PostHRT - postmenopausal women currently using hormone replacement therapy |
Primary outcome
MenoScale validity for menopause symptoms
Time frame: Baseline
The ability of the MenoScale to measure the prevalence of menopause-related symptoms in comparison to the most widely-used scale in clinical practice.
3 secondary outcomes
MenoScale validity for quality of life
Time frame: Baseline
MenoScale reliability
Time frame: Baseline and 1 week later
Diet quality
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2025.
- Background: PubMed 38171939Gatenby C, Simpson P. Menopause: Physiology, definitions, and symptoms. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101855. doi: 10.1016/j.beem.2023.101855. Epub 2023 Dec 21.
- Background: PubMed 36270905Bermingham KM, Linenberg I, Hall WL, Kade K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303. Epub 2022 Oct 18.
- Menopause transition: effects on women's economic participationLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Menopause
Not yet recruitingPhase 3
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Obesity
Not yet recruiting
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
Menopause, Menopausal Symptoms
Active, not recruitingObservational study
Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections
Urinary Tract Infections, Menopause
Recruiting
Hemodynamics After Resistance Training
Perimenopause
Not yet recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah Berry, PhD principal investigator
King's College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Menopause, run by Zoe Global Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MenoScale validity for menopause symptoms (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06800560, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.